Finance Operations Pharmaceuticals Power 
Marshall Goldsmith
FEBRUARY 8, 2018
a holding company that operates seven distinct business. Black Enterprise Magazine ‘Top 100 Most Powerful Executives in Corporate America’ and ‘50 Most Powerful Women in Corporate America’. Operations Group Baring Private Equity. Darek Lenart – Senior VP HR, Finance MasterCard. Former CEOs / Advisors.
Harvard Business Review
OCTOBER 26, 2011
Solyndra's example has been particularly stark: it raised over $1 billion in equity finance in addition to receiving a $535 million loan guarantee from the Department of Energy, all prior to a cancelled IPO and the recent FBI investigation upon its bankruptcy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
MAY 20, 2014
While there are numerous factors in such a massive shift away from business formation, one of the most powerful has to be the consolidation of multiple economic sectors toward a handful of firms with hegemonic power over their industry. In pharmaceuticals, the largest company, Pfizer, is the result of decades of mergers.
Harvard Business Review
APRIL 2, 2018
health care system, ranging from expensive imaging for benign medical conditions to routine pre-operative testing before low-risk surgeries like cataract surgery. Aside from reducing the use of low-value services, one potential solution is to identify and develop sources of long term financing for high-value services.
Harvard Business Review
NOVEMBER 10, 2017
Learning needs to be built into how power really works within organizations, organized around peer power, functional power, and hierarchical power. In one pharmaceutical R&D company, we identified three critical populations that needed to change to enable the execution of the organization’s strategy.
Harvard Business Review
FEBRUARY 4, 2013
Most of us would say it's exceptionally hard, particularly when power is concentrated in a few incumbent companies with deeply rooted vested interests. But this focused power may be a benefit, not a risk. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Finance.
Harvard Business Review
MAY 5, 2016
sanctions are delaying these projects being financed. And alongside the country’s bad debt (some estimates say it is $40 billion ), sanctions were commonly evaded through money laundering , which discouraged foreign banks from operating locally. Some powerful Iranian institutions are highly suspicious of Western influence.
Expert insights. Personalized for you.
70 
Let's personalize your content